News blog
Byotrol
- BY: Andrew Hore |
- POSTED: 16/06/2009 |
Byotrol says that it has generated revenues of more than £200,000 in the first two months of this financial year.
Byotrol has developed a technology that prevents microbes from reproducing. Trials at the Manchester Royal Infirmary have shown that Byotrol’s cleaning product has outperformed the standard. This will help Byotrol and its partner Synergy Health to sell to the NHS.
Byotrol has signed joint development agreements with Scholl, Durex and PZ Cussons for hygiene products.
Revenues dipped from £948,000 to £930,000 in the year to March 2009. The loss increased slightly from £2.77m to £2.98m. The figures were in line with revised forecasts after the trading statement in March. The cash outflow from operations was £2.81m.
Byotrol raised £3.75m after expenses from a placing at 11p a share in the autumn of 2008. There is £2.86m of cash in the bank. This cash should last for at least two years. Revenues of £4m are required to breakeven.
At 11p a share, Byotrol is valued at £9.21m. A £2m loss is forecast for the year to March 2010.
Ralph Kugler has been appointed as chairman.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|